Speaker Profile

Ph.D., Professor / CSO, UBC

Biography
Stirling Bryan is a health economist with a passion for building and supporting patient-oriented learning health systems. Before emigrating to Canada in 2008, Stirling held academic positions in the U.K. at St Thomas’ Hospital, Brunel University, and the University of Birmingham. He was a Commonwealth Fund Harkness Fellow in 2005/06, spending a year at Stanford University, and in 2020 was elected as a Fellow of the Canadian Academy of Health Sciences.


 Session Abstract – PMWC 2023 Silicon Valley


Track 1, Day 3

While innovative precision technologies can improve patient outcomes; they present new information and price shocks to payers. Emerging clinical guidelines may add to the confusion and further hamper payer acceptance. During this session, we’ll explore payer perspectives in the evidence evaluation processes that guide coverage decisions.

 Session Abstract – PMWC 2023 Silicon Valley


Track 1, January 27

Track Co-Chair:
Mary Relling, St. Jude

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Fireside Chat
    PMWC 2023 Pioneer Honoree Dan Roden, Vanderbilt University Medical Center with Mary Relling, St. Jude
  • PMWC 2023 Honoree Keynote
    - Kelly E. Caudle, St. Jude
  • Laboratory Testing and Reports
    Chair: Kristy Crooks, University of Colorado
    - Ann M. Moyer, Mayo Clinic
    - Stuart Scott, Stanford University
  • From Economics to Reimbursement
    Chair: Sara Rogers, American Society of Pharmacovigilance
    - Stirling Bryan, The University of British Columbia
    - Ray Stultz, Optum
  • Policy Efforts to Address Barriers to PGx Adoption
    Chair: Kristine Ashcraft, Invitae
    - Pam Traxel, ACS CAN
  • PGx Practice Liability
    - Dan Hertz, University of Michigan
    - Anthony Morreale, VA, San Diego
    - Karen Merritt, Patient Advocate
  • Diversity, Equity, and Inclusion in Pharmacogenomics Implementation
    - Carlos Bustamante, Galatea Bio
  • Implementation of PGx at UCSF
    - Bani Tamraz, UCSF